We are live on ! Find out more
TAK icon

Takeda Pharmaceutical
TAK

313 hedge funds and large institutions have $1.98B invested in Takeda Pharmaceutical in 2020 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 83 increasing their positions, 98 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 46

4% more capital invested

Capital invested by funds: $1.9B → $1.98B (+$79.2M)

1% more funds holding

Funds holding: 311 → 313 (+2)

0.08% more ownership

Funds ownership: 6.82% → 6.9% (+0.08%)

10% less call options, than puts

Call options by funds: $54.6M | Put options by funds: $60.5M

15% less repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 98

43% less funds holding in top 10

Funds holding in top 10: 7 → 4 (-3)

Holders
313
Holders Change
+2
Holders Change %
+0.64%
% of All Funds
5.54%
Holding in Top 10
4
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-42.86%
% of All Funds
0.07%
New
52
Increased
83
Reduced
98
Closed
46
Calls
$54.6M
Puts
$60.5M
Net Calls
-$5.85M
Net Calls Change
+$3.21M

Top Buyers

Rank Fund Capital Flow
1
AIM
ARK Investment Management
Florida
+$131M
2
N
Nuveen
North Carolina
+$21.5M
3
Wells Fargo
Wells Fargo
California
+$14.6M
4
TAM
TFG Asset Management
Cayman Islands
+$13.9M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$11.4M

Top Sellers

Rank Fund Capital Flow
1
LP
LMR Partners
United Kingdom
-$43.4M
2
GCM
Glenview Capital Management
New York
-$26.8M
3
Bank of America
Bank of America
North Carolina
-$22.3M
4
Citigroup
Citigroup
New York
-$16.9M
5
AC
Adelphi Capital
United Kingdom
-$12.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
CA
301
Clearstead Advisors
Ohio
$1K +$790 +45 New
BA
302
Bellwether Advisors
Nebraska
$1K +$1.23K +70 New
RA
303
Reby Advisors
Connecticut
$1K +$1.32K +75 New
TWM
304
Tradition Wealth Management
Minnesota
$1K +$1.32K +75 New
BCWM
305
Bartlett & Co Wealth Management
Ohio
$746 +$719 +41 New
ED
306
Exane Derivatives
France
$546 – – –
LP
307
LMR Partners
United Kingdom
– -$43.4M -2,446,614 Closed
Millennium Management
308
Millennium Management
New York
– -$9.2K -515,404 Closed
MS
309
Mizuho Securities
Japan
– -$3.86M -216,270 Closed
OMC
310
Old Mission Capital
Illinois
– -$3.03M -169,748 Closed
JAM
311
JCIC Asset Management
Ontario, Canada
– -$2.62M -146,710 Closed
AC
312
Asio Capital
Kentucky
– -$1.85M -103,665 Closed
SRAM
313
Spouting Rock Asset Management
Pennsylvania
– -$1.17M -65,522 Closed
FIA
314
FNY Investment Advisers
New York
– -$913K -51,200 Closed
LCM
315
Laurion Capital Management
New York
– -$835K -46,800 Closed
Squarepoint
316
Squarepoint
New York
– -$668K -37,434 Closed
ACI
317
AMP Capital Investors
Australia
– -$553K -30,470 Closed
HC
318
Henshaw Capital
Massachusetts
– -$542K -30,391 Closed
Ohio Public Employees Retirement System (OPERS)
319
Ohio Public Employees Retirement System (OPERS)
Ohio
– -$439K -24,600 Closed
HF
320
HRT Financial
New York
– -$386K -21,662 Closed
GT
321
Greenleaf Trust
Michigan
– -$348K -19,502 Closed
SSG
322
Summit Securities Group
New York
– -$265K -15,086 Closed
CG
323
Caprock Group
Idaho
– -$194K -10,887 Closed
SI
324
Stephens Inc
Arkansas
– -$190K -10,675 Closed
GC
325
Guggenheim Capital
Illinois
– -$188K -10,534 Closed
11 12
13
14 15

TAK Hedge Fund Activity: Q4 2020 in Review

313 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q4 2020, worth a combined $1.98B — up 4.2% from $1.9B a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new TAK positions and 46 closed out — a net gain of 6 holders — while 83 added to existing stakes and 98 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $131M. The largest seller was LMR Partners, exiting entirely with an estimated $43.4M sold.

  • 313 institutional investors held Takeda Pharmaceutical (TAK) as of Q4 2020, up from 311 in Q3 2020.
  • Funds reported $1.98B of Takeda Pharmaceutical stock for Q4 2020, up 4.2% quarter-over-quarter.
  • 52 funds opened new Takeda Pharmaceutical positions in Q4 2020 and 46 closed out, a net change of +6 holders.
  • The largest Takeda Pharmaceutical buyer in Q4 2020 was ARK Investment Management, an estimated $131M added.
  • The largest Takeda Pharmaceutical seller in Q4 2020 was LMR Partners, an estimated $43.4M sold.

Based on aggregated 13F filings for Q4 2020.